In January, the results of a long-term study on the effects of minors using cross-sex hormones were made public. The hormones prescribed to the participants were described as “gender-affirming hormones”—with such treatment regimens also referred to in the literature as “gender-affirming care” or “transgender medicine.”
Some 315 people between the ages of 12 and 20 were monitored for a period of two years to examine their “physical and psychosocial outcomes” after the administration of either testosterone or estradiol, a form of estrogen.
